Royal Bank Of Canada Eq Rx, Inc. Transaction History

Royal Bank Of Canada

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$1.66 - $2.31 $33,764 - $46,985	20,340 Added 61.1%	53,630 $119,000
Q2 2023 Aug 14, 2023	BUY	$1.61 - $1.96 $35,460 - $43,169	22,025 Added 195.52%	33,290 $61,000
Q1 2023 May 15, 2023	SELL	$1.8 - $2.83 $27,765 - $43,652	-15,425 Reduced 57.79%	11,265 $21,000
Q4 2022 Feb 14, 2023	BUY	$2.05 - $5.5 $40,421 - $108,449	19,718 Added 282.82%	26,690 $65,000
Q3 2022 Nov 14, 2022	BUY	$0.94 - $5.99 $5,828 - $37,143	6,201 Added 804.28%	6,972 $34,000
Q2 2022 Aug 15, 2022	SELL	$3.2 - $5.69 $11,107 - $19,749	-3,471 Reduced 81.82%	771 $4,000
Q1 2022 May 16, 2022	BUY	$2.8 - $7.39 $11,877 - $31,348	4,242 New	4,242 $18,000

67.8M

Ticker EQRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 448,140,992
Description
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EG...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.